# Ivermectin for Post Exposure Prophylaxis of Covid-19

> **NCT05231603** · PHASE3 · TERMINATED · sponsor: **Clinical Research Centre, Malaysia** · enrollment: 50 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ivermectin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05231603
- **Lead sponsor:** Clinical Research Centre, Malaysia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-16
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-10-11
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Poor response
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231603, "Ivermectin for Post Exposure Prophylaxis of Covid-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05231603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*